Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis.

Journal of neurology, neurosurgery, and psychiatry 2023 Jun

filter terms:

Natalizumab is effective in the treatment of multiple sclerosis (MS). In 2021, the European Medicines Agency approved the subcutaneous (SC) variant of natalizumab which can be used instead of intravenous administration. However, the course of drug levels varies between administration routes, and the Food and Drug Administration rejected the request for approval of natalizumab SC for reasons that were not disclosed. Our objective was to evaluate the course of natalizumab trough drug levels in patients who switched from natalizumab intravenous to SC on various treatment intervals. The NEXT-MS trial (N=382) investigates personalised treatment of natalizumab, in which infusion intervals are prolonged based on individual natalizumab trough drug levels. In 2021, an amendment was approved allowing participants to switch from intravenous to SC administration with frequent measurements of natalizumab drug levels and antidrug antibodies (ADAs). Results were compared with linear mixed model analyses. Until December 2022, 15 participants switched to SC natalizumab. Natalizumab drug levels with SC administration were on average 55% lower compared with intravenous administration (Exp (estimate) 0.45, 95% CI 0.39 to 0.53, p<0.001), leading to very low trough drug levels in three patients on extended treatment intervals. No natalizumab ADAs were detected during intravenous or SC treatment. None of the participants on natalizumab SC showed evidence of MS disease activity. Natalizumab trough drug levels can decrease after switching from natalizumab intravenous to SC administration. We advise to monitor trough drug levels in patients with low natalizumab drug levels during intravenous treatment, patients with higher body mass index or patients on extended treatment intervals who switch to SC administration of natalizumab. © Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Citation

Alyssa A Toorop, Zoé L E van Kempen, Maurice Steenhuis, Jessica Nielsen, L G F Sinnige, Gert van Dijk, Christiaan M Roosendaal, Edo P J Arnoldus, Elske Hoitsma, Birgit I Lissenberg-Witte, Brigit A de Jong, Bob W van Oosten, Eva M M Strijbis, Bernard M J Uitdehaag, Theo Rispens, Joep Killestein, NEXT-MS study group. Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis. Journal of neurology, neurosurgery, and psychiatry. 2023 Jun;94(6):482-486